Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Combination Of Neutrophil-to-lymphocyte Ratio And Serum Ca 19-9 As A Prognostic Factor In Pancreatic Cancer

Combination of neutrophil-to-lymphocyte ratio and serum CA 19-9 as a prognostic factor in pancreatic cancer

Juan Sebastián García-Herrera1, Wendy R Muñoz-Montaño2, Horacio N López-Basave1

  • 1Gastrointestinal Tumors Division, Surgical Oncology Department, Instituto Nacional de Cancerología, Mexico City, México.

Journal of Gastrointestinal Oncology
|September 16, 2024

Related Experiment Videos

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

4.2K
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

365
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.3K

View abstract on PubMed

Summary
This summary is machine-generated.

High neutrophil-to-lymphocyte ratio (NLR) and carbohydrate antigen 19-9 (CA 19-9) levels independently predict worse outcomes in pancreatic cancer. Combining these biomarkers offers superior prognostic value for overall survival and progression-free survival.

Area of Science:

  • Oncology
  • Biomarkers
  • Cancer Research

Background:

  • Serum carbohydrate antigen 19-9 (CA 19-9) is a traditional pancreatic cancer biomarker.
  • Emerging biomarkers, including those reflecting systemic immune and inflammatory responses, are being explored for prognostic value.

Purpose of the Study:

  • To evaluate the prognostic significance of pretreatment neutrophil-to-lymphocyte ratio (NLR) and serum CA 19-9 in pancreatic cancer patients.
  • To determine if combining NLR and CA 19-9 improves prognostic accuracy.

Main Methods:

  • Retrospective analysis of 153 pancreatic cancer patients.
  • Recorded pretreatment NLR and serum CA 19-9 values.
  • Survival analysis (overall survival and progression-free survival) was performed.
Keywords:
Neutrophil-to-lymphocyte ratio (NLR)biomarkerscarbohydrate antigen 19-9 (CA 19-9)pancreatic cancer

Related Experiment Videos

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

4.2K
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

365
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.3K

Main Results:

  • High NLR (≥2.4) and high CA 19-9 (≥553 U/mL) were independently associated with worse survival.
  • Five-year overall survival was 9% for low-NLR vs. 2% for high-NLR (P=0.008).
  • Five-year progression-free survival was 5.7% for low-NLR vs. 1.3% for high-NLR (P=0.007).
  • Five-year overall survival was 8.5% for low-CA 19-9 vs. 0% for high-CA 19-9 (P=0.002).
  • Five-year progression-free survival was 4.1% for low-CA 19-9 vs. 0% for high-CA 19-9 (P=0.005).
  • Combining both biomarkers (Group 1: low-NLR and low-CA 19-9) showed significantly better 5-year OS (11.8%) and PFS (8.6%) compared to Group 2 (P<0.001 and P=0.001, respectively).

Conclusions:

  • High NLR and high CA 19-9 are independent predictors of worse outcomes in pancreatic cancer.
  • Combining NLR and CA 19-9 offers enhanced prognostic significance compared to using either biomarker alone.
  • This combined approach improves prognostic accuracy for overall survival and progression-free survival in pancreatic cancer patients.
prognostic factors